Table 5.
Comparison of characteristics of EBIs and non-EBIs included in the PRS efficacy review (N = 65)
| Characteristic | 10 EBIs n (%) | 55 non-EBIs n (%) |
|---|---|---|
| Target population | ||
| MSM | 0 (0) | 1 (2) |
| Drug users/IDU only | 2 (20) | 9 (16) |
| High risk youth only | 0 (0) | 3 (5) |
| Women only | 0 (0) | 9 (16) |
| Men only | 0 (0) | 2 (4) |
| Race/ethnicity (not mutually exclusive) | ||
| Majority AA | 6 (60) | 27 (49) |
| Majority people of color (including AA, Hispanic, API, other) | 5 (50) | 26 (47) |
| Majority white | 0 (0) | 5 (9) |
| Target groupa | ||
| Treatment-experienced | 4 (40) | 27 (49) |
| Treatment-naïve | 1 (10) | 18 (33) |
| Both | 5 (50) | 4 (7) |
| Type of setting (not mutually exclusive) | ||
| Clinic | 6 (60) | 34 (62) |
| Community | 4 (40) | 1 (2) |
| Other | 2 (20) | 34 (62) |
| Unit of delivery | ||
| Individual only | 6 (60) | 41 (75) |
| Group only | 1 (10) | 6 (11) |
| Individual and group | 3 (30) | 8 (15) |
| Community | 0 (0) | 0 (0) |
| Deliverer (not mutually exclusive) | ||
| Clinic staff | 6 (60) | 24 (44) |
| Facilitator/other | 7 (70) | 41 (75) |
| Intervention sessions | ||
| Single-session discrete | 0 (0) | 2 (4) |
| Multi-session discrete | 3 (30) | 25 (45) |
| Repetitive dosing or combinationb | 7 (70) | 28 (51) |
| Outcomes measured | ||
| Adherence only | 2 (20) | 19 (35) |
| Viral load only | 1 (10) | 5 (9) |
| Both | 7 (70) | 31 (56) |
| At least one statistically significant positive intervention effectc | ||
| Yes | 10 (100) | 35 (64) |
| No | 0 (0) | 20 (36) |
| Sample size at baseline | ||
| Median | 226 | 77 |
| Follow-up time | ||
| Median time for first follow-up (in month) | 3 | 2 |
| Median time for last follow-up (in month) | 9 | 6 |
| Median retention | ||
| At first “good-evidence” follow-upd | 85 % | 81 % |
a
n = 6 non-EBIs did not target treatment naïve or experienced
b
Repetitive dosing or combination = includes interventions that had repetitive dosing and one or more discrete sessions
c
At least one statistically significant positive intervention effect on viral load or medication adherence outcomes
d
1-month post completion of intervention or 3-month post implementation of intervention